AI-driven antibody & protein design
Deriving antibody structures from sequence, optimising developability in silico and converting back to sequence — replacing empirical screening of large antibody libraries; large pharma deals (Novartis, 2024) but clinical success still to be shown.
1 · What it gives
AI-driven antibody and protein design derives a structure from sequence, optimises developability in silico and converts it back into a sequence. It replaces labour-intensive empirical screening that generates and evaluates large numbers of antibodies in mammalian cells. Major pharmaceutical firms such as Novartis entered multi-billion-dollar partnerships for AI-driven protein drug development as of 2024. The therapeutic monoclonal antibody market is projected at USD 300 billion by 2025.
2 · What it replaces 6
| D1 | Gas-fermented single-cell protein (methane, CO2 and industrial off-gas) instead of fishmeal and imported protein concentrates in feed Replaces: Fishmeal from reduction fisheries and imported soybean/rapeseed protein concentrates in compound feed (as a formula share) | FEED |
| D2 | On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, … | DIAG |
| D1 | Precision-fermentation dairy and egg proteins (whey, casein, ovalbumin) and fungal biomass protein (mycoprotein) instead of a share of antibiotic- and land-intensive animal protein Replaces: A share of conventional dairy and meat protein — and with it the antibiotics, antiparasitics, fertilizer and pesticide inputs of the … | NOVEL |
| D1 | Feed enzymes (phytase) and fermentation amino acids instead of inorganic phosphate and excess crude protein Replaces: Dicalcium phosphate / rock-phosphate P supplements in pig and poultry feed; excess soybean-meal crude protein (ammonia, nitrate pollution); … | FEED |
| D3 | Genomic selection in dairy cattle breeding instead of progeny testing Replaces: Progeny testing — choosing AI bulls only after their daughters' milk records were available (5–6 years per bull and large testing costs) | BREED |
| D3 | Glutamate and MSG by bacterial fermentation instead of protein hydrolysis and chemical synthesis Replaces: Hydrolysis of wheat gluten or soybean protein with hydrochloric acid (1909–1960s); acrylonitrile-based chemical synthesis (Japan, … | FOOD |
3 · How to implement 3 steps
- 1Predict structureDerive the antibody structure from its sequence.
- 2Optimise in silicoOptimise developability properties computationally.
- 3Convert back and testConvert the optimised structure back to a sequence and test it.
4 · Who delivers
Matched suppliers (matched automatically)
| Shield Biological Projects | Israel | Producer | active |
| Vland Biotech 蔚蓝生物 (SSE 603739) | China | Research / RTO | active |
| Sanergy | Kenya | Services / consulting | active |
| AKVA group | Norway | Services / consulting | active |
| Agroindustrias Amazonicas | Peru | Producer | active |
| Brevel | Israel | Producer | active |
| Entobel | Vietnam | Producer | active |
| Magalarva | Indonesia | Not classified | active |
| Marine Biotechnology Products- Mauritius | Mauritius | Producer | active |
| Miljøfluen® - Biologisk fluebekæmpelse til landbruget | Denmark | Services / consulting | active |
| Entologics | Brazil | Not classified | unknown |
| Henan Jiyuan Baiyun Industry Co., Ltd. | China | Producer | active |
Leading companies and institutes (from the brief)
Companies named in the sources: Generate:Biomedicines, Absci, Insitro, Atomwise, InveniAI, Aria Pharmaceuticals and Genesis Therapeutics. Others are matched by the portal under Bio-AI and Pharma & biologics.
5 · Rules & route to market
state registration within 45 working days after acceptance of documents (plus dossier and tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
Clinical development documentation must align with ICH Common Technical Document (CTD) standards. The sources name no further US rule specific to AI design.
European Union
The sources reviewed on 2026-10-16 identified no the EU regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
China
The sources reviewed on 2026-10-16 identified no China regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
6 · Money: tenders & grants
| Grant | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States | Oct 15, 2027 364 days |
| Grant | NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) National Institutes of Health · United States | Jul 5, 2029 993 days |
| Grant | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the … National Institutes of Health · United States | Aug 18, 2027 306 days |
| Grant | Circular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative … European Commission · EU | Feb 2, 2027 109 days |
| Grant | Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not … National Institutes of Health · United States | Jan 25, 2028 466 days |
7 · Tech stack & innovations
Main risks from the sources: sparse data on antibody properties, lack of robust benchmarking, and the continuing challenge of clinical success despite in-silico advances.
Sources 5
- Frontiersin.org — www.frontiersin.org 2026-10-16
- Nibn.go.jp — www.nibn.go.jp 2026-10-16
- Jst.go.jp — www.jst.go.jp 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16